Australia markets open in 8 hours 57 minutes
  • ALL ORDS

    7,317.50
    +36.90 (+0.51%)
     
  • AUD/USD

    0.7757
    +0.0033 (+0.42%)
     
  • ASX 200

    7,058.60
    +35.50 (+0.51%)
     
  • OIL

    63.33
    +0.18 (+0.29%)
     
  • GOLD

    1,765.10
    +28.80 (+1.66%)
     
  • BTC-AUD

    80,950.73
    -1,963.15 (-2.37%)
     
  • CMC Crypto 200

    1,376.68
    -4.27 (-0.31%)
     

World Epilepsy Drugs Market to Cross $5.8 Billion by 2027, in Spite of COVID-19 Disruptions - ResearchAndMarkets.com

·3-min read

The "Epilepsy Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Epilepsy Drugs Market to Reach $5.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Epilepsy Drugs estimated at US$ 4.6 Billion in the year 2020, is projected to reach a revised size of US$ 5.8 Billion by 2027, growing at a CAGR of 3.3% over the analysis period 2020-2027.

First Generation, one of the segments analyzed in the report, is projected to record a 2.5% CAGR and reach US$ 1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Second Generation segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 5.2% CAGR

The Epilepsy Drugs market in the U.S. is estimated at US$ 1.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$ 1.1 Billion by the year 2027 trailing a CAGR of 5.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2% and 2.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Third Generation Segment to Record 3.9% CAGR

In the global Third Generation segment, USA, Canada, Japan, China and Europe will drive the 3.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$ 1.2 Billion in the year 2020 will reach a projected size of US$ 1.5 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$ 752.6 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 42 Featured):

  • Abbott Laboratories, Inc.

  • Cephalon, Inc.

  • GlaxoSmithKline PLC

  • Johnson & Johnson

  • Novartis AG

  • Pfizer, Inc.

  • Sanofi Aventis S.A.

  • Shire PLC

  • Tansna Therapeutics, Inc.

  • UCB Pharma, Inc.

Key Topics Covered

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of COVID-19 and a Looming Global Recession

  • Global Competitor Market Shares

  • Epilepsy Drugs Competitor Market Share Scenario Worldwide (in %): 2020E

  • Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 42

For more information about this report visit https://www.researchandmarkets.com/r/t1jdj0

View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005484/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900